Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Vaxcyte Inc (PCVX)

332 + Investors. Track Smart Money conviction in PCVX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +41
Streak
2Q ▲
Buyers last Q
64%

Smart Money Signals — PCVX

Based on 333 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added PCVX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
333 hedge funds hold PCVX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q
+24 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 64% buying

201 buying113 selling
Last quarter: 201 funds were net buyers (70 opened a brand new position + 131 added to an existing one). Only 113 were sellers (84 trimmed + 29 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new PCVX position: 56 → 40 → 64 → 70. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 25% medium ■ 30% new
150 out of 333 hedge funds have held PCVX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +33% but shares only +15% — price-driven

Value
+32%
Shares
+14%
Last quarter: the total dollar value of institutional holdings rose +33%, but actual share count only changed +15%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

59 → 56 → 40 → 64 → 70 new funds/Q
New funds entering each quarter: 56 → 40 → 64 → 70. A growing number of institutions are discovering PCVX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 49% veterans vs 31% newcomers

■ 49% veterans ■ 20% 1-2yr ■ 31% new
Entry-cohort mix of 346 holders: 169 (49%) are 2+ year veterans, 69 entered 1–2 years ago, and 108 (31%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 44% AUM from top-100 funds

44% from top-100 AUM funds
55 of 330 holders are among the 100 largest funds by AUM, controlling 44% of total institutional value in PCVX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PCVX

In 2026 Q1, 201 hedge funds were net buyers of PCVX (70 opened a new position, 131 added to an existing one), while 113 reduced or exited (84 trimmed, 29 sold completely) — a 64% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. 44% of total institutional value in PCVX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +41 funds (more new holders than closures). Total institutional holders: 333.

Hedge Fund Ownership: PCVX

How many hedge funds hold PCVX — quarterly history vs. share price
Quarterly hedge fund ownership of PCVX vs. share price

Market Analysis: PCVX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PCVX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Vaxcyte Inc (PCVX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PCVX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
PCVX
-15.2%
XLV
+2.0%

PCVX outperformed XLV by -17.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
PCVX
-6.0%
XLV
+3.1%

Since the filing became public, PCVX outperformed XLV by -9.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Growing Institutional Interest

Quality funds are building positions — conviction is rising but not yet widespread.

33 top-rated funds 16 high-conviction
Consensus
6.6
/ 10
breadth
×
Elite
6.4
/ 10
conviction
Hedge Fund Positioning: PCVX
332 + Investors

Track Smart Money conviction in PCVX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 332 292 13.7%
13F Shares 164M 143M 14.58%
Total Value $8.69B $6.56B 32.52%
New Positions 69 64 +5
Increased Positions 131 93 +38
Closed Positions 29 52 -23
Reduced Positions 77 104 -27
Total Calls 9 6 50.0%
Total Puts 6 4 50.0%
PUT/CALL Ratio 0.67 0.67 Bullish

Statistics: PCVX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

332 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PCVX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PCVX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Pivotal bioVenture Partners Investment Advisor LLC 28.51% 1,372,425 $79.8M
2 University of Wisconsin Foundation 12.37% 239,749 $13.9M
3 Kynam Capital Management, LP 10.48% 2,922,335 $169.8M
4 Trails Edge Capital Partners, LP 8.82% 662,470 $38.5M
5 Saturn V Capital Management LP 8.68% 824,532 $47.9M
6 Jones Hill Capital LP 8.03% 644,831 $37.5M
7 Caligan Partners LP 7.97% 2,060,719 $119.7M
8 Ra Capital Management, L.P. 7.07% 11,474,599 $666.8M
9 Rosalind Advisors, Inc. 6.77% 290,000 $16.9M
10 Paradigm Biocapital Advisors LP 5.69% 4,793,020 $278.5M
11 Elmind Capital, LP 5.22% 316,500 $18.4M
12 Superstring Capital Management LP 4.59% 110,454 $6.4M
13 Deep Track Capital, LP 4.08% 4,300,000 $249.9M
14 Novo Holdings A/S 4.05% 860,000 $50.0M
15 Spruce Street Capital LP 3.43% 245,709 $14.3M
16 Ishara Investments LP 3.16% 57,400 $3.3M
17 Eversept Partners, LP 2.83% 924,193 $53.7M
18 NEXTBio Capital Management LP 2.57% 95,223 $5.5M
19 Boxer Capital Management, LLC 2.48% 325,000 $18.9M
20 Ikarian Capital, LLC 2.02% 428,682 $24.9M
21 Seven Fleet Capital Management LP 2.00% 108,450 $6.3M
22 HighVista Strategies LLC 2.00% 124,647 $7.2M
23 Bellevue Group AG 1.65% 1,190,697 $69.2M
24 Eventide Asset Management, LLC 1.32% 1,374,292 $79.8M
25 Maverick Capital Ltd 0.92% 1,377,738 $80.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Vaxcyte Inc (PCVX)

What does the Smart Money Trend signal show for PCVX?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added PCVX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for PCVX?

More buyers than sellers — 64% buying: Last quarter: 201 funds were net buyers (70 opened a brand new position + 131 added to an existing one). Only 113 were sellers (84 trimmed + 29 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for PCVX holders?

Elite ownership — 44% AUM from top-100 funds: 55 of 330 holders are among the 100 largest funds by AUM, controlling 44% of total institutional value in PCVX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held PCVX?

45% of holders stayed for 2+ years: 150 out of 333 hedge funds have held PCVX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Vaxcyte Inc (PCVX) following the 2026 Q1 hedge fund 13F filings?

As of today, PCVX has moved -6.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.1% for the XLV sector ETF — an outperformance of -9.1%. Since the quarter end (March 31, 2026), PCVX has gained -15.2% vs +2.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →